Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

DiaPep277 (DeveloGen).

Nick Giannoukakis¹

¹University of Pittsburgh School of Medicine, Diabetes Institute, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|November 2, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects.

Metabolism: clinical and experimental·2024

Same author

Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches.

Frontiers in endocrinology·2023

Same author

Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes.

Frontiers in endocrinology·2023

Same author

Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.

Frontiers in immunology·2023

Same author

Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663.

Diabetes·2022

Same author

Hydrogel Dressings for Chronic Wound Healing in Diabetes: Beyond Hydration.

Journal of pharmaceutics & drug delivery research·2022

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

DiaPep277, a peptide derived from heat shock protein 60, is being studied for type 1 diabetes treatment. Clinical trials are evaluating its potential to prevent and treat diabetes symptoms in prediabetic and adult patients.

Area of Science:

Immunology
Endocrinology
Biochemistry

Background:

Type 1 diabetes is an autoimmune disease characterized by the destruction of insulin-producing beta cells.
Current treatments focus on insulin replacement therapy, which does not prevent disease progression or complications.
There is a need for novel therapeutic strategies to prevent or reverse the autoimmune process in type 1 diabetes.

Purpose of the Study:

To evaluate the safety and efficacy of DiaPep277 in patients with type 1 diabetes.
To assess the potential of DiaPep277 to prevent the development of type 1 diabetes in at-risk individuals.
To investigate the immunomodulatory effects of DiaPep277 in the context of type 1 diabetes.

Main Methods:

Phase II clinical trials are being conducted by DeveloGen.

Related Experiment Videos

DiaPep277 is a 24-amino acid peptide based on residues 437 to 460 of heat shock protein 60.

The study population includes patients with established type 1 diabetes, newly diagnosed type 1 diabetes, prediabetic state, and latent autoimmune diabetes of the adult.

Main Results:

Preliminary data from ongoing clinical trials will be presented.
The results will focus on changes in glycemic control, immune markers, and clinical outcomes.
Safety and tolerability of DiaPep277 will be assessed.

Conclusions:

DiaPep277 shows promise as a novel therapeutic agent for type 1 diabetes.
Further clinical trials are warranted to confirm the efficacy and long-term safety of DiaPep277.
DiaPep277 may offer a new approach to managing and potentially preventing type 1 diabetes.